# RAW SEQUENCE LISTING ERROR REPORT

**BIOTECHNOLOGY
SYSTEMS
BRANCH**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: _09/831,047A_

Source: _PCT/09_

Date Processed by STIC: _9/20/2001_

**THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:**
1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY** or,
2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER VERSION 3.0 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.
Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:
http://www.uspto.gov/web/offices/pac/checker

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 09/831,047A

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1____ Wrapped Nucleics
Wrapped Aminos

The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2____ Invalid Line Length

The rules require that a line not exceed 72 characters in length. This includes white spaces.

3____ Misaligned Amino Numbering

The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4____ Non-ASCII

The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5____ Variable Length

Sequence(s)____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6____ PatentIn 2.0 "bug"

A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for **Artificial or Unknown sequences.**

7____ Skipped Sequences (OLD RULES)

Sequence(s) ____ missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i)   SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.

8____ Skipped Sequences (NEW RULES)

Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000

9____ Use of n's or Xaa's (NEW RULES)

Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10____ Invalid <213> Response

Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence

11____ Use of <220>

Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32)   (Sec. 1.823 of Sequence Rules)

12____ PatentIn 2.0 "bug"

Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13____ Misuse of n

n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

AMC/MH – Biotechnology Systems Branch – 08/21/2001

PCT09

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/831,047A

Input Set : A:\WST93AUSA.txt
Output Set: N:\CRF3\09202001\I831047A.raw

```
 4 <110> APPLICANT: The Wistar Institute of Anatomy and Biology
 5         The Trustees of the University of Pennsylvania
 6         Blaszczyk-Thurin, Magdalena
 7         Kieber-Emmons, Thomas
 9 <120> TITLE OF INVENTION: Compositions and Methods For Treatment of Cancer
11 <130> FILE REFERENCE: WST93PCT
13 <140> CURRENT APPLICATION NUMBER: US/09/831,047A
14 <141> CURRENT FILING DATE: 2001-06-30
16 <150> PRIOR APPLICATION NUMBER: 60/107,478
17 <151> PRIOR FILING DATE: 1998-11-06
19 <160> NUMBER OF SEQ ID NOS: 121
21 <170> SOFTWARE: PatentIn Ver. 2.0
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 12
25 <212> TYPE: PRT
26 <213> ORGANISM: Artificial Sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: Description of Artificial Sequence:
30         peptido-mimetic of a Lewis antigen
32 <400> SEQUENCE: 1
33 Asp Leu Trp Asp Trp Val Val Gly Lys Pro Ala Gly
34  1               5                   10
37 <210> SEQ ID NO: 2
38 <211> LENGTH: 12
39 <212> TYPE: PRT
40 <213> ORGANISM: Artificial Sequence
42 <220> FEATURE:
43 <223> OTHER INFORMATION: Description of Artificial Sequence:
44         peptido-mimetic of a Lewis antigen
46 <400> SEQUENCE: 2
47 Asp Ala Trp Asp Trp Val Val Gly Lys Pro Ala Gly
48  1               5                   10
51 <210> SEQ ID NO: 3
52 <211> LENGTH: 12
53 <212> TYPE: PRT
54 <213> ORGANISM: Artificial Sequence
56 <220> FEATURE:
57 <223> OTHER INFORMATION: Description of Artificial Sequence:
58         peptido-mimetic of a Lewis antigen
60 <400> SEQUENCE: 3
61 Asp Asp Trp Asp Trp Val Val Gly Lys Pro Ala Gly
62  1               5                   10
65 <210> SEQ ID NO: 4
66 <211> LENGTH: 12
67 <212> TYPE: PRT
68 <213> ORGANISM: Artificial Sequence
70 <220> FEATURE:
```

C--> 13
C--> 14

71 <223> OTHER INFORMATION: Description of Artificial Sequence:
72   peptido-mimetic of a Lewis antigen
74 <400> SEQUENCE: 4
75 Asp Tyr Trp Asp Trp Val Val Gly Lys Pro Ala Gly
76   1   5   10
79 <210> SEQ ID NO: 5
80 <211> LENGTH: 12
81 <212> TYPE: PRT
82 <213> ORGANISM: Artificial Sequence
84 <220> FEATURE:
85 <223> OTHER INFORMATION: Description of Artificial Sequence:
86   peptido-mimetic of a Lewis antigen
88 <400> SEQUENCE: 5
89 Asp Glu Trp Asp Trp Val Val Gly Lys Pro Ala Gly
90   1   5   10
93 <210> SEQ ID NO: 6
94 <211> LENGTH: 12
95 <212> TYPE: PRT
96 <213> ORGANISM: Artificial Sequence
98 <220> FEATURE:
99 <223> OTHER INFORMATION: Description of Artificial Sequence:
100   peptido-mimetic of a Lewis antigen
102 <400> SEQUENCE: 6
103 Asp Lys Trp Asp Trp Val Val Gly Lys Pro Ala Gly
104   1   5   10
107 <210> SEQ ID NO: 7
108 <211> LENGTH: 12
109 <212> TYPE: PRT
110 <213> ORGANISM: Artificial Sequence
112 <220> FEATURE:
113 <223> OTHER INFORMATION: Description of Artificial Sequence:
114   peptido-mimetic of a Lewis antigen
116 <400> SEQUENCE: 7
117 Asp Arg Trp Asp Trp Val Val Gly Lys Pro Ala Gly
118   1   5   10
121 <210> SEQ ID NO: 8
122 <211> LENGTH: 12
123 <212> TYPE: PRT
124 <213> ORGANISM: Artificial Sequence
126 <220> FEATURE:
127 <223> OTHER INFORMATION: Description of Artificial Sequence:
128   peptido-mimetic of a Lewis antigen
130 <400> SEQUENCE: 8
131 Asp Ser Trp Asp Trp Val Val Gly Lys Pro Ala Gly
132   1   5   10
135 <210> SEQ ID NO: 9
136 <211> LENGTH: 12
137 <212> TYPE: PRT
138 <213> ORGANISM: Artificial Sequence

```
140 <220> FEATURE:
141 <223> OTHER INFORMATION: Description of Artificial Sequence:
142        peptido-mimetic of a Lewis antigen
144 <400> SEQUENCE: 9
145 Asp Leu His Asp Trp Val Val Gly Lys Pro Ala Gly
                      5                   10
146    1
149 <210> SEQ ID NO: 10
150 <211> LENGTH: 12
151 <212> TYPE: PRT
152 <213> ORGANISM: Artificial Sequence
154 <220> FEATURE:
155 <223> OTHER INFORMATION: Description of Artificial Sequence:
156        peptido-mimetic of a Lewis antigen
158 <400> SEQUENCE: 10
159 Asp Leu Tyr Asp Trp Val Val Gly Lys Pro Ala Gly
                      5                   10
160    1
163 <210> SEQ ID NO: 11
164 <211> LENGTH: 12
165 <212> TYPE: PRT
166 <213> ORGANISM: Artificial Sequence
168 <220> FEATURE:
169 <223> OTHER INFORMATION: Description of Artificial Sequence:
170        peptido-mimetic of a Lewis antigen
172 <400> SEQUENCE: 11
173 Asp Leu Phe Asp Trp Val Val Gly Lys Pro Ala Gly
                      5                   10
174    1
177 <210> SEQ ID NO: 12
178 <211> LENGTH: 12
179 <212> TYPE: PRT
180 <213> ORGANISM: Artificial Sequence
182 <220> FEATURE:
183 <223> OTHER INFORMATION: Description of Artificial Sequence:
184        peptido-mimetic of a Lewis antigen
186 <400> SEQUENCE: 12
187 Asp Leu Met Asp Trp Val Val Gly Lys Pro Ala Gly
                      5                   10
188    1
191 <210> SEQ ID NO: 13
192 <211> LENGTH: 12
193 <212> TYPE: PRT
194 <213> ORGANISM: Artificial Sequence
196 <220> FEATURE:
197 <223> OTHER INFORMATION: Description of Artificial Sequence:
198        peptido-mimetic of a Lewis antigen
200 <400> SEQUENCE: 13
201 Asp Leu Ala Asp Trp Val Val Gly Lys Pro Ala Gly
                      5                   10
202    1
205 <210> SEQ ID NO: 14
206 <211> LENGTH: 12
207 <212> TYPE: PRT
```

```
208 <213> ORGANISM: Artificial Sequence
210 <220> FEATURE:
211 <223> OTHER INFORMATION: Description of Artificial Sequence:
212         peptido-mimetic of a Lewis antigen
214 <400> SEQUENCE: 14
215 Asp Leu Glu Asp Trp Val Val Gly Lys Pro Ala Gly
216   1               5                   10
219 <210> SEQ ID NO: 15
220 <211> LENGTH: 12
221 <212> TYPE: PRT
222 <213> ORGANISM: Artificial Sequence
224 <220> FEATURE:
225 <223> OTHER INFORMATION: Description of Artificial Sequence:
226         peptido-mimetic of a Lewis antigen
228 <400> SEQUENCE: 15
229 Asp Leu Asp Asp Trp Val Val Gly Lys Pro Ala Gly
230   1               5                   10
233 <210> SEQ ID NO: 16
234 <211> LENGTH: 12
235 <212> TYPE: PRT
236 <213> ORGANISM: Artificial Sequence
238 <220> FEATURE:
239 <223> OTHER INFORMATION: Description of Artificial Sequence:
240         peptido-mimetic of a Lewis antigen
242 <400> SEQUENCE: 16
243 Asp Leu Lys Asp Trp Val Val Gly Lys Pro Ala Gly
244   1               5                   10
247 <210> SEQ ID NO: 17
248 <211> LENGTH: 12
249 <212> TYPE: PRT
250 <213> ORGANISM: Artificial Sequence
252 <220> FEATURE:
253 <223> OTHER INFORMATION: Description of Artificial Sequence:
254         peptido-mimetic of a Lewis antigen
256 <400> SEQUENCE: 17
257 Asp Leu Arg Asp Trp Val Val Gly Lys Pro Ala Gly
258   1               5                   10
261 <210> SEQ ID NO: 18
262 <211> LENGTH: 12
263 <212> TYPE: PRT
264 <213> ORGANISM: Artificial Sequence
266 <220> FEATURE:
267 <223> OTHER INFORMATION: Description of Artificial Sequence:
268         peptido-mimetic of a Lewis antigen
270 <400> SEQUENCE: 18
271 Asp Leu Ser Asp Trp Val Val Gly Lys Pro Ala Gly
272   1               5                   10
275 <210> SEQ ID NO: 19
276 <211> LENGTH: 12
```

```
277 <212> TYPE: PRT
278 <213> ORGANISM: Artificial Sequence
280 <220> FEATURE:
281 <223> OTHER INFORMATION: Description of Artificial Sequence:
282        peptido-mimetic of a Lewis antigen
284 <400> SEQUENCE: 19
285 Asp Leu Trp Glu Trp Val Val Gly Lys Pro Ala Gly
286   1               5                   10

289 <210> SEQ ID NO: 20
290 <211> LENGTH: 12
291 <212> TYPE: PRT
292 <213> ORGANISM: Artificial Sequence
294 <220> FEATURE:
295 <223> OTHER INFORMATION: Description of Artificial Sequence:
296        peptido-mimetic of a Lewis antigen
298 <400> SEQUENCE: 20
299 Asp Leu Trp Ser Trp Val Val Gly Lys Pro Ala Gly
300   1               5                   10

303 <210> SEQ ID NO: 21
304 <211> LENGTH: 12
305 <212> TYPE: PRT
306 <213> ORGANISM: Artificial Sequence
308 <220> FEATURE:
309 <223> OTHER INFORMATION: Description of Artificial Sequence:
310        peptido-mimetic of a Lewis antigen
312 <400> SEQUENCE: 21
313 Asp Leu Trp Pro Trp Val Val Gly Lys Pro Ala Gly
314   1               5                   10

317 <210> SEQ ID NO: 22
318 <211> LENGTH: 12
319 <212> TYPE: PRT
320 <213> ORGANISM: Artificial Sequence
322 <220> FEATURE:
323 <223> OTHER INFORMATION: Description of Artificial Sequence:
324        peptido-mimetic of a Lewis antigen
326 <400> SEQUENCE: 22
327 Asp Leu Trp Val Trp Val Val Gly Lys Pro Ala Gly
328   1               5                   10

331 <210> SEQ ID NO: 23
332 <211> LENGTH: 12
333 <212> TYPE: PRT
334 <213> ORGANISM: Artificial Sequence
336 <220> FEATURE:
337 <223> OTHER INFORMATION: Description of Artificial Sequence:
338        peptido-mimetic of a Lewis antigen
340 <400> SEQUENCE: 23
341 Asp Leu Trp Met Trp Val Val Gly Lys Pro Ala Gly
342   1               5                   10

345 <210> SEQ ID NO: 24
```

```
<210> SEQ ID NO 100
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
      peptido-mimetic of a Lewis antigen

<400> SEQUENCE: 100
      Asn Leu Arg Pro Lys Tyr Ile Xaa Leu Asp Ala Asp
      1               5               10
```

See item 9 on Error Summary Sheet

same error in Seqs. 111-112

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/831,047A

Input Set : **A:\WST93AUSA.txt**
Output Set: **N:\CRF3\09202001\I831047A.raw**

L:13 M:270 C: Current Application Number differs, Replaced Application Number
L:14 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:1419 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:100
L:1419 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:100
L:1419 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:100
L:1573 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:111
L:1573 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:111
L:1573 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:111
L:1587 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:112
L:1587 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:112
L:1587 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:112